
Peptide amidation is the conversion of a peptide’s C-terminal carboxyl group into an amide (-CONH2). The amide is the new terminus, not an extra side chain, and it does not lengthen the mature peptide. In the biological pathway, the reaction starts with a glycine-extended precursor: the extra glycine supplies the amide nitrogen, while its carbon skeleton leaves as glyoxylate. The preceding residue becomes the amidated terminal residue. Many bioactive peptides require this modification for full activity. The amide is not made by transamidation; it is produced by oxidative cleavage of the glycine N-C-alpha bond.[1]
The Chemistry: A New Terminal Group, Not an Added Side Chain
A free-acid peptide ends in -COOH, which is largely -COO- at physiological pH. An amidated peptide ends in -CONH2. The difference is the terminal functional group: the acidic carboxyl is replaced by a neutral amide. This removes the terminal negative charge; it does not necessarily make the whole peptide neutral, because other groups in the molecule contribute to its charge.[2]
Two comparisons help avoid confusion about chain length. The free-acid and amidated versions of the same mature sequence contain the same number of amino-acid residues. By contrast, the biosynthetic precursor contains an extra C-terminal glycine. PAM converts that n+1-residue precursor into an n-residue amidated peptide, consuming molecular oxygen and releasing the glycine-derived carbon skeleton as glyoxylate.[2] Thus, amidation does not extend the mature sequence, but PAM processing does shorten the glycine-extended precursor by one residue.
Peptide-OH and peptide-NH2 can therefore refer to the same core sequence with different C-termini, whereas peptide-Gly names a different precursor sequence. These distinctions matter when comparing experiments: a terminal-group comparison is not the same chemical comparison as precursor versus mature product.
The Enzymatic Route: PHM Hydroxylates, PAL Cleaves

In higher organisms, the conversion is catalyzed by peptidylglycine alpha-amidating monooxygenase (PAM), a bifunctional polypeptide with two catalytic activities.[1] The reactions act in sequence rather than transferring a ready-made amide group to the peptide.[3]
The first step is catalyzed by peptidylglycine alpha-hydroxylating monooxygenase (PHM). PHM hydroxylates the glycine alpha-carbon of peptidylglycine substrates stereospecifically. It contains two redox-active copper atoms. After reduction by ascorbate, those copper centers support the reduction of molecular oxygen and hydroxylation of the glycine-extended substrate. The immediate product is peptidyl-alpha-hydroxyglycine.[1]
The second step is catalyzed by peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL). PAL cleaves the hydroxyglycine intermediate to release the alpha-amidated peptide and glyoxylate.[1] The glycine-derived nitrogen remains attached to the preceding residue’s carbonyl, forming its terminal amide; the glycine carbons leave in the coproduct. This explains why the final amide belongs to the preceding residue rather than to a retained terminal glycine.[2]
PHM acts on peptidylglycine substrates and has broad substrate specificity. The required substrate feature is an exposed C-terminal glycine on the precursor; many different sequences can lie upstream of that glycine. A specific flanking-residue consensus is not established by the material cited here.[1]
Why the C-Terminus Matters

Changing a carboxylate to an amide removes a negative charge at the terminus and can change the peptide’s interactions with its surroundings. Greater hydrophobic character and altered receptor recognition are chemical rationales for functional differences, not a universal prediction that amidation improves binding.[2] The terminal carboxylate is anionic and accepts hydrogen bonds; the neutral primary amide presents two N-H bonds capable of donating hydrogen bonds. This changes the terminus’s hydrogen-bond presentation and surface complementarity. It is a structural rationale, not evidence for a particular binding pose.
The functional consequence can be large even when the rest of the sequence is identical. In ex vivo human platelet experiments, PAR1 and PAR4 activating peptides with a C-terminal amide were consistently more potent than their free-acid counterparts. Median EC50 values were 2.6 to 12.6 times lower for amidated PAR1 agonists and 4.7 to 10 times lower for amidated PAR4 agonists. These ratios describe short synthetic agonist pairs in platelet assays, not clinical results or a general amidation multiplier.[4]
A peptide-hormone example comes from amylin, also called islet amyloid polypeptide. Its mature C-terminal residue is amidated Tyr37. Replacing that amide with a carboxylate reduced activation 58-fold at the amylin 1 receptor and 20-fold at the amylin 3 receptor in cell-based assays summarized in the amylin paper. These are receptor-activation results, not direct measurements of binding affinity, and the effect is specific to this peptide and these receptor systems.[5]
Other signaling peptides processed by PAM include neuropeptide Y and alpha-melanocyte-stimulating hormone, alongside amylin. Their shared dependence on terminal processing spans different peptide sequences and biological roles.[6] Their inclusion in this pathway does not make their functions interchangeable.
Does Amidation Protect Peptides from Degradation?
Amidated peptides are described in the amylin paper’s literature discussion as less susceptible to proteolytic degradation, which can extend their half-lives in the bloodstream.[5] The structural rationale concerns carboxypeptidases that recognize a free C-terminal carboxylate: amidation removes that recognition feature. This is a rationale for resistance to that route of attack, not a claim that every exopeptidase or other protease is blocked.
No direct carboxypeptidase assay or plasma stability measurement for amidated peptides was read for this article. The cited general statement therefore supports a possible stability advantage, not a measured half-life for a particular material. Receptor activation and proteolytic stability are separate properties; a larger response in a receptor assay does not by itself establish slower degradation.
What the Evidence Shows Across Systems
Enzyme and membrane research
Molecular simulations of uperin 3.5, an amyloid-forming antimicrobial peptide, illustrate how the terminal group can change membrane behavior. Monomeric U3.5-NH2 attached rapidly to a POPE:DOPG lipid bilayer and formed a stable alpha-helix, whereas U3.5-OH interacted more weakly. In tetramer simulations, amidation enhanced peptide-bilayer and peptide-peptide interactions. The initially stabilized beta-sheet tetramers later dissociated into monomers on the membrane surface. These are computational predictions for one peptide in one lipid mixture, not direct measurements in cells or organisms.[7]
Amidation can also be studied outside animal cells. Recombinant Caenorhabditis elegans PHM was expressed in the yeast Pichia pastoris and used in a study demonstrating C-terminal amidation of ubiquitin. This establishes a biotechnology application of the enzyme rather than a therapeutic result. PHM supplies the hydroxylation activity; it should not be confused with the two-activity PAM pathway described above.[8]
Animal and human-islet data
Beta-cell-specific Pam knockout mice had impaired second-phase glucose- and KCl-induced insulin secretion. Their beta cells had larger dense-core granules and fewer, shorter cilia. Non-amidated human IAPP was less fibrillogenic in vitro, and high-glucose-treated islets in the human-IAPP mouse model had a reduced amyloid burden after beta-cell Pam deletion. Despite these changes, the knockout mice were not more susceptible to diet-induced hyperglycemia.[6]
Deleting Pam is also not equivalent to changing only one peptide’s terminal group. PAM participates in vesicle and membrane trafficking as well as amidation, so a knockout phenotype cannot automatically be assigned to one missing amide.[6]
Human islet data add a tissue-level observation: PAM enzyme activity was significantly reduced in islets from donors carrying the PAM p.Asp563Gly type 2 diabetes-risk allele.[6] That links a genotype to enzyme activity in human tissue. It is distinct from both a mouse knockout experiment and a clinical test of changing amidation in people.
Where the Reaction Occurs in the Secretory Pathway
Amidation is a late processing step in the secretory pathway. Amylin provides a concrete sequence of events: prohormone convertases cleave after a dibasic site, carboxypeptidase E removes the remaining C-terminal dibasic residues, and PAM uses the exposed C-terminal glycine to form the mature amide.[5] In this processing sequence, the trimming enzymes prepare the substrate that PAM recognizes; their cleavage-site requirements should not be mistaken for an additional universal PAM motif.
PAM itself exists in integral membrane and soluble forms. Tissue-specific alternative splicing governs the presence of a transmembrane domain, and endoproteolytic processing can release soluble PAM from membrane-bound precursors. Soluble PAM is stored in the regulated secretory granules characteristic of neurons and endocrine cells.[9] The evidence places this processing in the secretory pathway and identifies granule storage, without fixing both catalytic steps to one precise organelle.
How to Read an Amidation Claim
A useful comparison identifies the complete peptide structure and the experimental endpoint. A glycine-extended precursor, a mature free-acid peptide, and its amidated counterpart are different molecules. An enzyme conversion experiment addresses processing; a receptor assay addresses activation under its assay conditions; a mouse knockout addresses the consequences of losing PAM in that model. These are not interchangeable endpoints.
The PAR1/PAR4 study specifically recommends reporting the complete peptide structure because results obtained with one terminal form should not be assumed to apply to the other.[4] For a comparison of peptide-OH and peptide-NH2, the important conclusion is not that one suffix is universally better. It is that the terminal group is part of the molecule being tested, and a change there can alter the experimental result.
Related research: Peptide Identity: Sequences, Fragments, Modifications, Salt Forms; Selank vs N-Acetyl Selank Amidate: Masses and Salt Forms; Semax vs N-Acetyl Semax Amidate: Structure and Identity.
Research Use Only. This article is for laboratory research and analytical education, not a validated experimental protocol or medical or veterinary advice; it is not guidance for administration to humans or animals.
References
- New insights into copper monooxygenases and peptide amidation: structure, mechanism and function
- Peptidylglycine alpha-amidating monooxygenase
- Peptide amidation
- Impact of C-terminal amidation on platelet activation by PAR1 and PAR4 activating peptides
- On the importance of being amidated: analysis of the role of the conserved C-terminal amide of amylin in amyloid formation and cytotoxicity
- PAM is important in mice for beta-cell cilia formation and insulin secretion but promotes diabetes risk through beta-cell independent mechanisms
- C-Terminal Amidation: Structural Insights into Enhanced Antimicrobial Peptide Efficacy and Amyloidogenesis
- Efficient production of peptidylglycine alpha-hydroxylating monooxygenase in yeast for protein C-terminal functionalization
- Peptidylglycine alpha-amidating monooxygenase: a multifunctional protein with catalytic, processing, and routing domains